A clinical study published in the American Health & Drug Benefits journal describes the Mitomic Prostate Core Test’s impact on patient management and the biopsy decision-making process.
The diagnostics game has changed dramatically over the past 15 years. Old-school companies placed their bets on high-volume, low-margin tests, but today’s molecular diagnostics players are all about value proposition. The market is hungry for simple tests that impact patient outcomes while also taking costs out of the system.
Chris Mitton Appointed Chief Executive Officer; Jack Riccardi Appointed Chief Financial Officer.
MDNA Life Sciences will present at the Biotech Showcase 2016 to be held January 11-13, 2016, at the Parc 55 San Francisco.
Performance measurements from the first phase of our ongoing two-part validation study for the Prostate Core Mitomic Test™ for prostate cancer yield positive results.